1. Home
  2. SNBR vs CHRS Comparison

SNBR vs CHRS Comparison

Compare SNBR & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sleep Number Corporation

SNBR

Sleep Number Corporation

N/A

Current Price

$5.30

Market Cap

188.2M

ML Signal

N/A

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

N/A

Current Price

$1.94

Market Cap

186.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SNBR
CHRS
Founded
1987
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
188.2M
186.0M
IPO Year
1998
2014

Fundamental Metrics

Financial Performance
Metric
SNBR
CHRS
Price
$5.30
$1.94
Analyst Decision
Hold
Strong Buy
Analyst Count
3
4
Target Price
$10.00
$5.51
AVG Volume (30 Days)
665.9K
1.7M
Earning Date
01-01-0001
04-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
109.88
EPS
N/A
1.77
Revenue
$1,682,296,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$79.63
P/E Ratio
N/A
$1.03
Revenue Growth
N/A
N/A
52 Week Low
$3.49
$0.72
52 Week High
$13.94
$2.62

Technical Indicators

Market Signals
Indicator
SNBR
CHRS
Relative Strength Index (RSI) 27.56 58.84
Support Level $3.73 $1.55
Resistance Level $8.94 $2.62
Average True Range (ATR) 0.73 0.09
MACD -0.32 0.01
Stochastic Oscillator 9.39 96.05

Price Performance

Historical Comparison
SNBR
CHRS

About SNBR Sleep Number Corporation

Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: